<DOC>
	<DOCNO>NCT02466906</DOCNO>
	<brief_summary>This study investigate efficacy safety rhGM-CSF adjuvant immunotherapy patient resectable stage III colon cancer .</brief_summary>
	<brief_title>RhGM-CSF Adjuvant Immunotherapy Treating Stage III Colon Cancer</brief_title>
	<detailed_description>This study investigate efficacy safety rhGM-CSF adjuvant immunotherapy patient resectable stage III colon cancer . Patients randomly assign rhGM-CSF group placebo group treat rhGM-CSF placebo perioperation adjuvant chemotherapy . The purpose study evaluate antitumor immune effect rhGM-CSF surgery adjuvant chemotherapy DFS 5 year observe safety treatment order provide evidence improvement treat resectable colon cancer patient .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Molgramostim</mesh_term>
	<criteria>1 . Diagnosed resectable stage III colon cancer 2 . 1870 year old 3 . ECOG performance status ≤2 4 . Unexposed rhGMCSF 6 month 5 . Signed informed consent document 1 . Secondary primary cancer , concurrent primary malignancy ( except basal cell squamous cell skin cancer , cervical cancer situ , cancer disease free 5 year ) 2 . Complete intestinal obstruction 3 . Events within 6 month randomization : myocardial infarction , sever unstable angina , coronary artery peripheral arterial bypass surgery , congestive heart failure ( NYHA functional class III IV ) , stroke myocardial dysfunction transient ischaemic attack 4 . Abnormal liver kidney function ( Serum creatinine &gt; 1.5 x ULN , total bilirubin &gt; 1.5 x ULN , transaminase &gt; 3 x ULN ) , abnormal pulmonary function ( FEV1 &lt; 60 % diffusing capacity lung carbon monoxide &lt; 55 % ) 5 . Bone marrow dysfunction ( Hb &lt; 9.0 g/dL、ANC &lt; 1.5 x 109/L、PLT &lt; 100 x 109/L ) 6 . ITP immunodeficiency 7 . Uncontrolled infection , include HBV , HCV , HIV infection 8 . Female patient pregnant planning , lactation 9 . Known allergic E.coli agent rhGMCSF severe allergic history drug 10 . Other case researcher find ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Stage III colon cancer</keyword>
	<keyword>rhGM-CSF</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Surgery</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
</DOC>